Cargando…

Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model

The availability of a safe and effective vaccine would be the eventual measure to deal with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) threat. Here, we have assessed the immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidates BBV152A, BBV152B, and BBV152...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohandas, Sreelekshmy, Yadav, Pragya D., Shete-Aich, Anita, Abraham, Priya, Vadrevu, Krishna Mohan, Sapkal, Gajanan, Mote, Chandrashekhar, Nyayanit, Dimpal, Gupta, Nivedita, Srinivas, Vellimedu Kannappa, Kadam, Manoj, Kumar, Abhimanyu, Majumdar, Triparna, Jain, Rajlaxmi, Deshpande, Gururaj, Patil, Savita, Sarkale, Prasad, Patil, Deepak, Ella, Raches, Prasad, Sai D., Sharma, Sharda, Ella, Krishna M., Panda, Samiran, Bhargava, Balram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829205/
https://www.ncbi.nlm.nih.gov/pubmed/33521604
http://dx.doi.org/10.1016/j.isci.2021.102054
_version_ 1783641138227314688
author Mohandas, Sreelekshmy
Yadav, Pragya D.
Shete-Aich, Anita
Abraham, Priya
Vadrevu, Krishna Mohan
Sapkal, Gajanan
Mote, Chandrashekhar
Nyayanit, Dimpal
Gupta, Nivedita
Srinivas, Vellimedu Kannappa
Kadam, Manoj
Kumar, Abhimanyu
Majumdar, Triparna
Jain, Rajlaxmi
Deshpande, Gururaj
Patil, Savita
Sarkale, Prasad
Patil, Deepak
Ella, Raches
Prasad, Sai D.
Sharma, Sharda
Ella, Krishna M.
Panda, Samiran
Bhargava, Balram
author_facet Mohandas, Sreelekshmy
Yadav, Pragya D.
Shete-Aich, Anita
Abraham, Priya
Vadrevu, Krishna Mohan
Sapkal, Gajanan
Mote, Chandrashekhar
Nyayanit, Dimpal
Gupta, Nivedita
Srinivas, Vellimedu Kannappa
Kadam, Manoj
Kumar, Abhimanyu
Majumdar, Triparna
Jain, Rajlaxmi
Deshpande, Gururaj
Patil, Savita
Sarkale, Prasad
Patil, Deepak
Ella, Raches
Prasad, Sai D.
Sharma, Sharda
Ella, Krishna M.
Panda, Samiran
Bhargava, Balram
author_sort Mohandas, Sreelekshmy
collection PubMed
description The availability of a safe and effective vaccine would be the eventual measure to deal with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) threat. Here, we have assessed the immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidates BBV152A, BBV152B, and BBV152C in Syrian hamsters. Three dose vaccination regimes with vaccine candidates induced significant titers of SARS-CoV-2-specific IgG and neutralizing antibodies. BBV152A and BBV152B vaccine candidates remarkably generated a quick and robust immune response. Post-SARS-CoV-2 infection, vaccinated hamsters did not show any histopathological changes in the lungs. The protection of the hamster was evident by the rapid clearance of the virus from lower respiratory tract, reduced virus load in upper respiratory tract, absence of lung pathology, and robust humoral immune response. These findings confirm the immunogenic potential of the vaccine candidates and further protection of hamsters challenged with SARS-CoV-2. Of the three candidates, BBV152A showed the better response.
format Online
Article
Text
id pubmed-7829205
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78292052021-01-26 Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model Mohandas, Sreelekshmy Yadav, Pragya D. Shete-Aich, Anita Abraham, Priya Vadrevu, Krishna Mohan Sapkal, Gajanan Mote, Chandrashekhar Nyayanit, Dimpal Gupta, Nivedita Srinivas, Vellimedu Kannappa Kadam, Manoj Kumar, Abhimanyu Majumdar, Triparna Jain, Rajlaxmi Deshpande, Gururaj Patil, Savita Sarkale, Prasad Patil, Deepak Ella, Raches Prasad, Sai D. Sharma, Sharda Ella, Krishna M. Panda, Samiran Bhargava, Balram iScience Article The availability of a safe and effective vaccine would be the eventual measure to deal with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) threat. Here, we have assessed the immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidates BBV152A, BBV152B, and BBV152C in Syrian hamsters. Three dose vaccination regimes with vaccine candidates induced significant titers of SARS-CoV-2-specific IgG and neutralizing antibodies. BBV152A and BBV152B vaccine candidates remarkably generated a quick and robust immune response. Post-SARS-CoV-2 infection, vaccinated hamsters did not show any histopathological changes in the lungs. The protection of the hamster was evident by the rapid clearance of the virus from lower respiratory tract, reduced virus load in upper respiratory tract, absence of lung pathology, and robust humoral immune response. These findings confirm the immunogenic potential of the vaccine candidates and further protection of hamsters challenged with SARS-CoV-2. Of the three candidates, BBV152A showed the better response. Elsevier 2021-01-09 /pmc/articles/PMC7829205/ /pubmed/33521604 http://dx.doi.org/10.1016/j.isci.2021.102054 Text en © 2021 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Mohandas, Sreelekshmy
Yadav, Pragya D.
Shete-Aich, Anita
Abraham, Priya
Vadrevu, Krishna Mohan
Sapkal, Gajanan
Mote, Chandrashekhar
Nyayanit, Dimpal
Gupta, Nivedita
Srinivas, Vellimedu Kannappa
Kadam, Manoj
Kumar, Abhimanyu
Majumdar, Triparna
Jain, Rajlaxmi
Deshpande, Gururaj
Patil, Savita
Sarkale, Prasad
Patil, Deepak
Ella, Raches
Prasad, Sai D.
Sharma, Sharda
Ella, Krishna M.
Panda, Samiran
Bhargava, Balram
Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model
title Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model
title_full Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model
title_fullStr Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model
title_full_unstemmed Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model
title_short Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model
title_sort immunogenicity and protective efficacy of bbv152, whole virion inactivated sars- cov-2 vaccine candidates in the syrian hamster model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829205/
https://www.ncbi.nlm.nih.gov/pubmed/33521604
http://dx.doi.org/10.1016/j.isci.2021.102054
work_keys_str_mv AT mohandassreelekshmy immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel
AT yadavpragyad immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel
AT sheteaichanita immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel
AT abrahampriya immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel
AT vadrevukrishnamohan immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel
AT sapkalgajanan immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel
AT motechandrashekhar immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel
AT nyayanitdimpal immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel
AT guptanivedita immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel
AT srinivasvellimedukannappa immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel
AT kadammanoj immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel
AT kumarabhimanyu immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel
AT majumdartriparna immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel
AT jainrajlaxmi immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel
AT deshpandegururaj immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel
AT patilsavita immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel
AT sarkaleprasad immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel
AT patildeepak immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel
AT ellaraches immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel
AT prasadsaid immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel
AT sharmasharda immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel
AT ellakrishnam immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel
AT pandasamiran immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel
AT bhargavabalram immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel